Stocks
I
BSX I
Jul 24, 2024, 11:59:05 AM
Boston Scientific Reports Robust Second Quarter 2024 Results
Marlborough, Mass., July 24, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) announced its financial results for the second quarter of 2024, showcasing significant growth and strong financial performance.
Financial Highlights:
- Net Sales: $4.120 billion, a 14.5% increase on a reported basis, 16.1% on an operational basis, and 14.7% on an organic basis compared to Q2 2023.
- GAAP Net Income: $324 million, or $0.22 per share, up from $261 million, or $0.18 per share, in Q2 2023.
- Adjusted EPS: $0.62, compared to $0.53 in the prior year.
Mike Mahoney, CEO of Boston Scientific, stated, "We delivered a quarter marked by exceptional performance, reflecting our global team's relentless pursuit of innovation supported by strong clinical evidence and strategic investments."
Segment and Regional Performance:
-
MedSurg Segment:
- Endoscopy: 7.1% reported, 8.4% operational, and 7.9% organic growth.
- Urology: 8.2% reported, 9.1% operational, and 9.1% organic growth.
- Neuromodulation: 15.5% reported, 16.2% operational, and 3.7% organic growth.
-
Cardiovascular Segment:
- Cardiology: 20.1% reported, 22.0% operational, and 22.0% organic growth.
- Peripheral Interventions: 10.2% reported, 12.3% operational, and 9.4% organic growth.
-
Regional Growth:
- U.S.: 16.9% reported and operational growth.
- EMEA: 13.7% reported, 16.1% operational growth.
- APAC: 7.0% reported, 13.2% operational growth.
- LACA: 15.3% reported, 15.7% operational growth.
- Emerging Markets: 14.8% reported, 19.3% operational growth.
Key Developments:
Full Year and Third Quarter 2024 Guidance:
-
Full Year 2024:
- Net Sales Growth: 13.5% to 14.5% on a reported basis, 13% to 14% on an organic basis.
- GAAP EPS: $1.34 to $1.38.
- Adjusted EPS: $2.38 to $2.42.
-
Third Quarter 2024:
- Net Sales Growth: 13% to 15% on both reported and organic basis.
- GAAP EPS: $0.36 to $0.38.
- Adjusted EPS: $0.57 to $0.59.
Source: BSX